A prospective multicenter evaluation of direct molecular detection of blood stream infection from a clinical perspective by unknown
RESEARCH ARTICLE Open Access
A prospective multicenter evaluation of
direct molecular detection of blood stream
infection from a clinical perspective
A. E. Nieman1,9, P. H. M. Savelkoul1,2, A. Beishuizen3,4, B. Henrich5, B. Lamik5, C. R. MacKenzie5, D. Kindgen-Milles6,
A. Helmers7, C. Diaz7, S. G. Sakka8 and R. P. Schade1*
Abstract
Background: Rapid diagnosis and appropriate antimicrobial therapy are of major importance to decrease morbidity
and mortality in patients with blood stream infections (BSI). Blood culture, the current gold standard for detecting
bacteria in blood, requires at least 24–48 hours and has limited sensitivity if obtained during antibiotic treatment of
the patient. The aim of this prospective multicenter study was to clinically evaluate the application of a commercial
universal 16S/18S rDNA PCR, SepsiTest™ (PCR-ST), directly on whole blood.
Methods: In total 236 samples from 166 patients with suspected sepsis were included in the study. PCR-ST results
were compared to blood culture, the current gold standard for detecting BSI. Because blood cultures can give
false-negative results, we performed an additional analysis to interpret the likelihood of bloodstream infection by
using an evaluation based on clinical diagnosis, other diagnostic tests and laboratory parameters.
Results: Clinical interpretation of results defined the detected organism to be contaminants in 22 of 43 positive
blood cultures (51.2 %) and 21 of 47 positive PCR-ST results (44.7 %). Excluding these contaminants resulted in an
overall sensitivity and specificity of the PCR-ST of 66.7 and 94.4 % respectively. Of the 36 clinically relevant samples,
11 BSI were detected with both techniques, 15 BSI were detected with PCR-ST only and 10 with blood culture only.
Therefore, in this study, SepsiTest™ detected an additional 71 % BSI compared to blood culture alone.
Conclusions: More clinically relevant BSI were diagnosed by molecular detection, which might influence patient
treatment. An improved SepsiTest™ assay suited for routine use can have additional value to blood culture in
diagnosing bacteremia in septic patients.
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Background
Blood stream infection is a serious clinical condition
with high morbidity and mortality rates. Sepsis, severe
sepsis and septic shock are associated with high mortal-
ity, ranging from 20 to 60 % depending on severity and
underlying disease [1–4]. Sepsis is defined as a systemic
inflammatory response syndrome (SIRS) in addition to
documented or presumed infection. Severe sepsis is
sepsis associated with organ dysfunction, hypoperfusion,
or hypotension. Septic shock is the persistence of
hypotension and perfusion abnormalities despite ad-
equate resuscitation therapy [5]. Bacteremia, the pres-
ence of bacteria within the bloodstream, which leads to
SIRS or sepsis, is associated with high morbidity and
mortality. Rapid diagnosis of BSI and early initiation of
appropriate antimicrobial treatment significantly de-
creases morbidity and mortality. Appropriate therapy in
septic patients within the first hour of documented
hypotension was associated with a survival rate of 80 %,
with an average decrease of 7,6 % in survival every hour,
up to 6 h, that antibiotics were delayed [6]. Empiric
antimicrobial therapy is correct in approximately 85–
90 % of blood stream infections [7–10]. As soon as
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microbiological results are available, inappropriate anti-
biotics can be adjusted.
Currently, automated blood culture systems are the
standard technique to diagnose BSI, however, blood cul-
tures have several disadvantages. First, the minimum
time to detection and identification of the causative or-
ganism is 24–48 h. Secondly, the sensitivity is approxi-
mately 70 % for critically ill patients and even lower for
fastidious microorganisms [11]. Thirdly, prior adminis-
tration of antibiotics significantly reduces the sensitivity
of blood culture, sometimes even up to 100 % [12–15].
These disadvantages can potentially be overcome by
molecular techniques performed directly on blood with-
out culture. Polymerase chain reaction (PCR) targeting
microbial DNA performed directly on blood is a rapid
technique with a processing time of only a few hours.
PCR detection of bacterial or fungal DNA is not
dependent on the presence of replicating organisms and
can be detected from intact dead or living bacteria. The
major technological drawback to apply PCR assays for
diagnosing blood stream infection is inhibition of the
PCR amplification by relatively large amounts of pro-
teins and human DNA in whole blood samples that cur-
rently limits the sample volume to approximately 200 μl
of whole blood [14]. Human DNA in leukocytes and
proteins, like immunoglobulin G, heme in erythrocytes
and lactoferrin in leukocytes all interfere with the
process by binding DNA polymerase or binding the nu-
cleic acids [16–21]. However, optimization of DNA iso-
lation and new methods that selectively purify microbial
DNA to circumvent inhibition by human DNA have
been developed. In this way higher volumes of blood
can be processed which theoretically reduces sampling
error and increases sensitivity. SepsiTest™ is not the only
technique in this field, several other commercial tests
have been developed that use PCR or time-of flight mass
spectrometry for fast identification of pathogens, i.e.
SeptiFast, MALDI-TOF on blood culture and more re-
cently PCR ESI/MS (IRIDICA). The SeptiFast assay is a
multiplex PCR performed directly on whole blood. Sen-
sitivity compared to blood culture was 12–67 % depend-
ing on the microorganism, with a specificity of 81–98 %
[22, 23] and the clinical sensitivity of the SeptiFast assay,
excluding contaminants, was 62–70 % [24]. A recent
randomized trial showed a significant reduction in the
time required from sampling to providing pathogen
identification to the clinician, with a mean duration of
15.9 h for PCR compared to 38.1 h for blood culture
[25]. A drawback of this technique is the limited number
of bacterial and fungal pathogens, 25 in total, in this
multiplex PCR, and the low sensitivity. The next tech-
nique, MALDI-TOF in combination with the commer-
cial Sepsityper kit allows identification on positive blood
cultures with a reliable detection of 76 % of Gram-
positive microorganisms and 90 % of Gram-negative mi-
croorganisms [26]. Of course the major drawback of this
method is the necessity to culture first, which takes ap-
proximately 1–2 days and delays the time-to-result com-
pared to direct tests on blood. More recently IRIDICA
has been developed, a technique that combines multi-
plex PCR directly on whole blood with electrospray
ionization mass spectrometry (PCR ESI/MS). Sensitivity
and specificity compared to blood culture were 83 and
78–94 % and sensitivity and specificity of the test com-
pared with the clinical infection criterion were 91 and
87 % [27, 28]. This seems a promising technique, how-
ever publications so far are limited.
We here present a prospective multicenter study that
investigates the SepsiTest™ assay (Molzym, Bremen,
Germany) in 1 ml of whole blood from patients on in-
tensive care units with clinically suspected sepsis. The
SepsiTest™ assay selectively degrades human DNA, be-
fore isolation of the microbial DNA. SepsiTest™ can pro-
vide a positive or negative result within 4 h and needs
additional sequencing to identify the microorganism,
which takes another 2–3 h if sequencing is available in
the laboratory. Clinical relevance and routine applicabil-
ity of this approach was evaluated by comparing the
PCR results to blood culture, C-reactive protein, other
microbiological investigations and patient data. This
study shows that molecular detection of BSI has a po-
tential benefit for patients suffering from sepsis however,
several improvements of the technique are still required.
Methods
This study was conducted as a multicenter trial with pa-
tients suspected of sepsis. From each patient routine
blood cultures and EDTA blood for PCR with the Sep-
siTest™ assay were taken. The study was performed in
three participating centers: Medical Center Cologne-
Merheim, University Witten/Herdecke in Cologne,
Germany; Heinrich Heine University Hospital in Düssel-
dorf, Germany and VU University Medical Center in
Amsterdam, The Netherlands. The study was approved
by the Institutional Ethical Board of each center. Blood
sampling was incorporated in routine patient care, with-
out additional written informed consent. Blood samples
for PCR-ST were collected; DNA extraction, PCR and
sequencing were performed retrospectively. As this was
an observational study, results of PCR-ST were not
shared with the clinicians. Treatment of the patient was
based on cultures and clinical signs and symptoms.
Patient selection
In total 166 patients were included in the three centers.
The collection period was 5 months for each center, in
the time period from November 2010 to September
2012. Inclusion criteria were patients ≥18 years old,
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admitted to the intensive care unit with systemic inflam-
matory response syndrome (SIRS) or suspected sepsis. If
the treating physician had a clinical suspicion of SIRS or
sepsis, blood was taken for culture and PCR-ST.
Sample and data collection
Samples for blood culture and PCR-ST were collected
from the same blood vessel puncture according to the
hospital’s standardized aseptic procedures. For blood
culture 10 ml of blood was drawn into an aerobic and
anaerobic blood culture bottle each, and inoculated in
BACTEC™ FX (Beckton Dickinson) or BacT/ALERT®
(bioMérieux) depending on the participating center.
Blood cultures were incubated for a maximum of 5 days.
For PCR-ST, an additional volume of 4 ml of EDTA
blood was collected. Identification of the organism in
positive blood culture was performed with conventional
methods as customary in each laboratory. All laborator-
ies were certified according to the national quality stand-
ard for clinical microbiological laboratories.
Other samples were taken according to the suspected
cause of infection, e.g. sputum, wound swabs, pus or
urine. C-reactive protein and leucocyte count were re-
corded on the day of blood sample collection. Primary
and secondary diagnosis, antibiotics used in the past
48 h and hospital inpatient mortality were registered.
DNA isolation with SepsiTest™
Fresh EDTA blood was divided into two aliquots of 1 ml
and processed according to the SepsiTest™ manufac-
turer’s manual. In short, a chaotropic buffer was first
added to the blood samples that selectively lysed the
blood cells. Then, the released nucleic acids were de-
graded by adding MolDNase. After enrichment by cen-
trifugation, the sediment was treated with BugLysis and
ß-mercaptoethanol to lyse cell walls of potentially
present bacteria and yeasts. Proteinase K and a final
chaotropic buffer was added for extra cell lysis and de-
naturation of proteins. The pathogen DNA was isolated
by a bind-wash-elute procedure and eluated in a final
volume of 100 μl. All materials used during these steps
were sterile and nucleic acid-free to avoid laboratory and
handling contamination. Sterile and nucleic acid free
buffers and tubes were provided in the SepsiTest™ kit.
Sterile pipette tips were used. Handling of samples was
performed in a laminar flow cabinet that was disinfected
and treated with UV light after each use.
PCR and amplicon detection
The protocol for PCR-ST was performed according to
the manufacturer’s manual. Mastermixes for universal
PCR, internal control, and negative and positive controls
were available in the kit. Five μl of eluate (~50 μl EDTA
blood) of each duplicate sample were tested, with
internal inhibition tested separately. All PCR-STs were
performed on Piko Thermal Cyclers (Finnzymes).
Amplicons were detected with electrophoresis on 2 %
agarose gel. A sample was considered positive if at least
one of the duplicates was positive with a blank negative
control.
Sequencing
Positive amplicons were purified with QIAquick PCR
Purification Kit (Qiagen) and sent to GATC Biotech
(Germany) for sequencing with primers provided in the
kit. Acquired sequences were identified with SepsiTest™
BLAST, or with NCBI BLAST when results were not
available in SepsiTest™ BLAST. The organism was iden-
tified at a genus level if the sequence homology was ≥97
and <99 % and at a species level if ≥99 % according to
the manufacturer’s manual. For samples with weak
bands on agarose gel and insufficient quality of sequen-
cing results, the PCR, amplicon detection and sequen-
cing were repeated. If sequencing results still had
insufficient quality, the sample was considered negative.
Definitions
Positive samples were divided into 4 categories: true,
probable, possible and questionable bacteremia. Identical
bacteria detected both in blood culture and PCR-ST was
considered as true bacteremia. For discordant results an
interpretation of the likelihood of bacteremia was made
according to the following definitions: bacteremia was
considered probable if the pathogen was also cultured in
other specimens of the same patient and consistent with
the clinical diagnosis; possible if the pathogen was not
confirmed in other cultures, but considered to be con-
sistent with the clinical diagnosis. The result was inter-
preted as questionable bacteremia if the microorganism
was not confirmed by other microbiological results and
was not considered a likely cause of sepsis. In this case
we defined the microorganism as a contaminant.
Results of other specimens, i.e. urine culture, wound
swabs etc., were taken into account when sampled
within 48 h before or after the positive blood culture or
positive PCR-ST.
A polymicrobial result, i.e. a sample which yielded
more than one microorganism in the same sample, was
considered as true, probable or possible bacteremia,
when one of the detected microorganisms met the defi-
nitions for true, probable or possible.
Statistical analysis
Sensitivity and specificity of PCR-ST by using blood cul-
ture as gold standard were calculated both on sample
and patient level. Statistics were calculated based on
paired samples, i.e. blood culture with corresponding
PCR-ST sample. Subsequently, to investigate the
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potential additional value of PCR-ST in diagnosing BSI,
the sensitivity and specificity of the PCR-ST were also
calculated including clinical interpretation of results.
Based on the above definitions, positive samples were di-
vided into: true, probable, possible and questionable BSI.
True, probable and possible BSI were regarded as posi-
tive, and questionable as negative for the calculation of
an adjusted sensitivity and specificity.
Results
In this study, 166 patients were included with a total of
236 blood samples. The mean age of the patients was
65 years, with a range from 26 to 92 years. Sixty-three
women were included (38 %). From all blood samples 43
of the 236 were positive by blood culture (18.2 %) and
47 were positive by PCR-ST (19.9 %). Samples matched
in 72 % of cases. After excluding contaminants 91 % of
the samples matched.
Sensitivity and specificity of the SepsiTest™ assay com-
pared to blood culture was 25.6 and 82.9 % respectively,
with negative and positive predictive values of 84.7 and
23.4 % (sample level, Table 1). When analyzed for the
166 patients, sensitivity and specificity were 28.9 and
79.7 %, with a negative and positive predictive value of
81.0 and 27.5 % (patient level).
The majority of detected microorganisms were staphylo-
cocci in both blood culture and PCR-ST (Table 2). Coagu-
lase negative staphylococci (CoNS) were found in blood
cultures in 30 of the 43 positive cultures (69.8 %). Staphylo-
coccus aureus was found in 2 blood cultures. For PCR-ST,
identification to species level was not always possible. CoNS
were detected by PCR-ST in 13 of 47 positive samples
(27.7 %) whereas S. aureus was detected in 6 cases (12.8 %).
Staphylococcus spp. not further identified, were detected in
an additional 9 samples (19.1 %). It was not possible to
distinguish between coagulase negative staphylococci or
Staphylococcus aureus for these 9 samples, due to insuffi-
cient quality of the sequencing fragment at the site of dis-
tinction. In total, 32 staphylococci (74.4 %) were detected
with blood culture compared to 28 (59.6 %) with PCR-ST.
Gram-negative rods were found in two samples with blood
culture (4.7 %) and in six samples with PCR-ST (12.8 %).
Candida was found in only one sample with each tech-
nique, however in different samples.
Polymicrobial samples, i.e. samples with more than
one microorganism, were detected in only one blood
culture (2.3 %), but were common in the PCR-ST results
(12 samples, 25.5 %) (Table 3). It is to be noted that 9
out of 12 polymicrobial PCR-ST results were found in
one center (75 %).
Evaluation of PCR-ST results to blood culture as gold
standard may result in lower sensitivity when clinically
contaminated blood cultures are defined as positive. On
the other hand, specificity may be hampered by false
negative blood cultures due to antibiotic therapy or bac-
teria that are difficult to culture. Based on the combin-
ation of lab results and clinical interpretation of the
Table 1 Results of BC and PCR-ST without clinical interpretation
BC positive BC negative Total
PCR-ST positive 11 + 3a 33 47
PCR-ST negative 29 160 189
Total 43 193 236
Abbreviations: BC blood culture, PCR-ST polymerase chain reaction
with SepsiTest™
aThree samples were positive in both BC and PCR-ST, however the microorgan-
isms detected were different. For calculating sensitivity and specificity of PCR-ST
compared to BC only concordant results were included
Table 2 Microorganisms detected in sepsis patients with PCR-ST
alone, blood culture alone or detected with both methods
True, probable and possible bacteremia
PCR-ST BC both
Monomicrobial
Staphylococcus aureus 3 1 1
Coagulase negative Staphylococci (CoNS) 2 3 5a
Staphylococcus spp. 1 0 1
Enterococcus spp. 1 3 3b
Streptococcus pneumoniae 1 0 0
Escherichia coli 1 1 0
Klebsiella oxytoca 0 0 1
Candida albicans 1 1 0




Coagulase negative Staphylococci 5 20
Staphylococcus spp. 3 0
Propionibacterium spp. 0 2
Streptococcus spp. 4 0
Enterococcus spp. 1 0
Lactococcus lactis 1 0
Rickettsia symbiont 1 0
Corynebacterium spp. 1 0
Polymicrobialc 5 0
PCR-ST BC both
Total 36 32 11
Abbreviations: PCR-ST polymerase chain reaction with SepsiTest™, BC blood
culture, spp. species
aone sample contained CoNS in blood culture and CoNS + Corynebacterium
in PCR-ST
bone sample contained Enterococcus faecalis in blood culture and Enterococcus+
Streptococcus spp in PCR-ST
cfor microorganisms detected in polymicrobial samples, see Table 3
In total 236 samples were analyzed of which 79 were positive in one or both
methods. Results are presented by likelihood of bacteremia, true/probable/
possible versus questionable bacteremia
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microorganism with respect to the patient’s disease, 22
of 43 positive blood cultures of in total 236 samples
were considered to be contaminants. This is 51,2 % of
positive blood cultures and 9,3 % of all blood cultures.
For PCR-ST 21 of 47 positive results were considered to
be contaminants (44,7 %), i.e. 8,9 % of all samples. For
example, a septic patient with the clinical signs of a
thrombophlebitis of the lower arm and a Staphylococcus
aureus detected in both blood culture and PCR-ST, was
considered to have a true bacteremia. A patient with
peritonitis and a negative blood culture, however
Enterococcus spp. detected with PCR-ST that had also
Enterococcus faecium in peritoneal cultures was consid-
ered to have probable bacteremia. On the other hand, a
Corynebacterium detected with PCR-ST that was not de-
tected in any other culture and is known to be a com-
mon contaminant, was considered as questionable
bacteremia. After clinical interpretation of all positive
results (Table 4), the adjusted sensitivity and specificity on
sample level was 66.7 and 94.4 %. The negative and positive
predictive value was 96.7 and 53.8 % respectively. In total
36 samples were considered clinically relevant as detected
by PCR-ST, blood culture or both. Of these 36 samples, 11
microorganisms were detected by both methods, 15 were
detected by PCR-ST only and 10 by blood culture only.
Of 28 patients with clinically relevant positive blood
samples, 13 (47 %) had a respiratory or an intra-
abdominal cause of sepsis (Table 5). From these patients
22/28 (78.6 %) had received antibiotics in the 48 h prior
to testing. Of discordant results, i.e. a positive result
in either blood culture or PCR-ST alone, 8 patients
with previous antibiotics had a PCR-ST positive result
only, compared to 6 patients with positive blood cul-
tures only.
This study clearly indicates that clinical interpretation
of PCR-ST results is important, as is true for blood cul-
ture. The additional value of PCR-ST in diagnosing BSI
is substantial; an extra 15 bacteremias confirming the
clinical perspective were detected compared to 21
with blood culture alone (71 %). These results may
Table 3 Microorganisms detected in polymicrobial samples with PCR-ST and blood culture
True, probable and possible bacteremia
PCR-ST BC
Polymicrobial
Enterococcus spp, Coagulase negative Staphylococci 0 1
Staphylococcus aureus, Lactobacillus spp. 1 0
Escherichia coli, Streptococcus mitis group 1 0
Pseudomonas aeruginosa, Acinetobacter lwoffii, Staphylococcus warneri, Streptococcus equi 1 0
Escherichia coli, Edwardsiella ictaluri, Enterococcus faecium, Staphylococcus aureus 1 0




Lactobacillus spp., Enterococcus mundtii 1 0
Haemophilus parainfluenzae, Haemophilus ducreyi, Neisseria wadsworthii, Lactococcus lactis 1 0
Staphylocccus spp., Streptococcus spp 1 0
Lactobacillus spp., Staphylocccus spp., Streptococcus spp. 1 0
Abiotropha paraadiacens/Granulicatella adiacens, Staphylococcus spp., Streptococcus spp. 1 0
PCR-ST BC
Total 10a 1
Abbreviations: PCR-ST polymerase chain reaction with SepsiTest™, BC blood culture, spp. species
aTwo additional polymicrobial PCR-ST results are listed in Table 2: these samples contained two microorganisms in the PCR-ST and one concordant microorganism
in the corresponding BC
A polymicrobial sample, a sample that yielded more than one microorganism, was considered as true, probable or possible bacteremia, when one of the detected
microorganisms met the definitions for true, probable or possible, regardless of the meaning of the other microorganisms
Table 4 Results of BC and PCR-ST after excluding contaminants
BC positive BC negative Total
PCR-ST positive 14a 12 26
PCR-ST negative 7 203 210
Total 21 215 236
Abbreviations: BC blood culture, PCR-ST polymerase chain reaction with SepsiTest™
aThree samples were positive in both BC and PCR-ST, however the microorgan-
isms detected were different. Since both microorganisms were considered
clinically relevant these samples were included as possible/probable blood
stream infections in the adjusted sensitivity
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influence antimicrobial therapy in terms of type, dose
and duration.
Discussion
A rapid diagnosis of BSI is of major importance for pa-
tient outcome. A direct PCR on whole blood, instead of
blood culture, should theoretically reduce the time to
diagnosis and implementation of adequate antimicrobial
therapy.
In this multicenter study we have evaluated the per-
formance of a universal PCR assay in patients suspected
of sepsis. Sensitivity and specificity were based on com-
paring PCR-ST with blood culture, on both sample and
patient level. To determine the actual clinical relevance
of these PCR-ST results, all positive samples were also
analyzed after a clinical interpretation of the micro-
organism detected in respect to other diagnostic tests,
and the patient’s disease. Despite the fact that the total
numbers of relevant microorganisms were small, with 21
relevant blood cultures and 26 relevant PCR-ST results
in a total of 236 samples, the performance of the
SepsiTest™ within a clinical context was verified.
Sensitivity of PCR-ST compared to blood culture, with-
out clinical interpretation of results, was only 33 % with
a specificity of 83 % (sample level). A previous study
showed similar specificity (85.8 %), but much higher sen-
sitivity (87 %) of the SepsiTest™ assay compared to blood
culture [29]. The same test and a comparable patient
population were evaluated but we found a higher num-
ber of blood cultures with coagulase negative staphylo-
cocci that were considered to be a contamination (47 %
of positive BC). In routine application, clinical interpret-
ation of results is crucial for clinical use of both blood
culture as well as PCR-ST. In 9 of 47 positive PCR-ST
results Staphylococcus spp. were found. Due to insuffi-
cient quality of the sequencing fragment at the site of
distinction it was not possible to differentiate between
Staphylococcus aureus and coagulase negative staphylo-
cocci. This is a shortcoming of the test, since coagulase
negative staphylococci are often contaminants while
Staphylococcus aureus is a clinically relevant pathogen.
More than 40 % of positive results in both blood culture
and PCR-ST were considered contaminants, based on
clinical diagnosis, laboratory parameters and other
microbiological tests performed in the same individual.
In the majority of these results coagulase negative
staphylococci were found in blood culture and staphylo-
cocci and streptococci were found in PCR-ST. A recent
study of 1334 patients with positive blood cultures also
showed significant numbers of contaminants. In this
study 55,8 % of blood cultures were considered bacterial
contamination, compared to 44,2 % true blood stream
infections [15]. After clinical interpretation of results,
the adjusted sensitivity and specificity were 66.7 and
94.4 % respectively. For clinical interpretation we made
some assumptions as described in the methods. Ques-
tionable bacteremia as defined in this study may actually
be true bacteremia and possible bacteremia may be actu-
ally contaminants. This is a drawback of the calculated
adjusted sensitivity and specificity. However, in daily
practice it is very common to make a clinical evaluation
of the microorganism found in the blood culture,
especially for coagulase negative staphylococci and cer-
tain streptococci. For PCR-ST a clinical interpretation is
also important. Interpretation errors may limit these
calculations.
In studies evaluating PCR directly on whole blood,
other than SepsiTest™, low sensitivities were also found
compared to blood culture results. For the SeptiFast
assay, Josefson and Grif showed a sensitivity on sample
level of 12–67 and 63 % respectively [22, 23]. Clinical
sensitivity, after excluding contaminants, was 62–70 %
(Bravo et al.) [24]. In these studies a multiplex PCR with
a select number of microorganisms was used to detect
bacteremia. Bacteria that were not included in the multi-
plex PCR were logically not detectable with this ap-
proach. However, this explained only in part the low
sensitivity since the majority of microorganisms missed
were included in the PCR panel but were only detected
by blood culture [22–24, 30].
An explanation for the low sensitivity in most studies
as well as in our study is possibly the large difference in
input volume used in blood culture compared to PCR.
For one blood culture bottle, 8–10 ml of blood was used.
For PCR, an amount equal to 50 μl of whole blood was
tested. This means that the amount of blood tested in
one blood culture bottle is around 200 times more than
in one PCR reaction. The chance of sampling error in
PCR is therefore much higher, especially when low
amounts of bacteria are present in the blood of the pa-
tient. This can be improved by using 50 μl of eluate and
Table 5 Focus of infection in patients with positive blood
culture and/or PCR results considered true, probable or possible












Nieman et al. BMC Infectious Diseases  (2016) 16:314 Page 6 of 9
10 μl of DNA in the PCR although the amount of blood
tested in a blood culture bottle will still be 50 times
more. If higher input volumes for PCR can be used, sen-
sitivity of PCR on blood will increase [16–21].
Specificity was more in line with blood culture, how-
ever it is debatable whether blood culture is a reliable
gold standard. In our samples we found many staphylo-
cocci and considered more than 50 % of positive blood
cultures (mostly CoNS) clinically irrelevant. On the
other hand, blood cultures may be false negative. The
sensitivity of blood culture increases if more blood cul-
tures are obtained, from approximately 65–73 % for 1
set of blood culture bottles (20 ml), 80–90 % for two sets
and 95–99 % for 3 sets of blood cultures. As a conse-
quence one negative blood culture cannot exclude BSI
[31, 32]. Therefore, the presence of microorganisms de-
tected by PCR may reflect actual disease. Moreover, the
microorganisms can truly be temporarily present in
blood, as is known for short bacteremias after dental
procedures [33–35] and surgical procedures [36, 37].
Mostly, these bacteremias do not cause a systemic in-
flammatory response syndrome and therefore no BSI.
These are true bacteremias, but not clinically relevant.
Of course, in a universal PCR technique the chance of
contamination of the sample in the laboratory is also
substantial. Clean handling of samples throughout the
entire procedure from withdrawal to PCR is of utmost
importance. Obviously, for both PCR-ST and blood cul-
ture, the detected microorganisms need to be evaluated
in the clinical context to decide whether the result is
more likely to be clinically relevant or contamination.
Theoretically, the advantage of blood culture is that
one viable bacterium is sufficient for a positive result.
High volumes of blood can be tested at once, and the
possibility of testing antibiotic susceptibility makes blood
culture a valuable technique. PCR on the other hand is
useful for microorganisms that are difficult or impossible
to culture, after the initiation of antibiotic therapy and
can be performed directly on whole blood, thus elimin-
ating the incubation time, which is important for early
adequate antimicrobial therapy.
The SepsiTest™ assay is a complex method with many
buffers, enzymes and reagents to be added and several
centrifugation steps before the eluate is obtained.
Hands-on-time and the possibility of laboratory contam-
ination can be reduced by automation of this procedure
and replacing gel electrophoresis by melting curve ana-
lysis to detect positive samples. The SepsiTest™ assay is
now designed as a positive or negative result with subse-
quent sequencing to identify the bacteria. DNA extrac-
tion and PCR-ST can be performed within 4 h and
produces a negative or positive result. Only a positive re-
sult needs to be sequenced for identification of the
microorganism. This adds 2 to 3 h to the time-to-
results, provided that sequencing is available in the la-
boratory. In our study, sequencing was outsourced
which increased the turnaround time. In routine practice
however this could be performed within 6–7 h until
complete identification. The test can be used without se-
quencing, with only a positive or negative result. How-
ever, owing to the substantial chance of contamination, a
clinical interpretation of results is necessary and there-
fore the identification of the microorganism. With the
current setup of this method, the theoretical advantage
of a fast PCR directly on whole blood is reduced by the
complex handling procedure and the need for sequen-
cing to identify the microorganism.
Conclusions
This study in 166 patients with sepsis indicates that dir-
ect molecular detection of bacteria is of added value to
blood culture in detecting blood stream infections. An
additional 71 % of BSI were detected by the SepsiTest™
assay (PCR-ST) compared to blood culture alone. Fur-
thermore, after antibiotic therapy, slightly more BSI were
detected by PCR-ST than by blood culture. Overall,
PCR-ST results may influence the administration of ad-
equate antimicrobial therapy and diminish patient’s mor-
bidity and mortality. Although the SepsiTest™ PCR
directly on blood is a promising technique, the input
volume of blood should be increased to lower sampling
error, and a faster procedure to identify the microorgan-
ism is of importance. The current universal microbial
PCR is not a substitute for blood culture but may be of
additional clinical value in diagnosing BSI. In general,
from a clinical perspective a rapid molecular whole
blood test is of added value for patient treatment.
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